— Know what they know.
Not Investment Advice

AGIO

Agios Pharmaceuticals, Inc.
1W: +19.3% 1M: +15.9% 3M: +24.6% YTD: +24.5% 1Y: +11.7% 3Y: +55.6% 5Y: -29.5%
$35.20
+1.01 (+2.95%)
After Hours: $33.80 (-1.40, -3.98%)
Weekly Expected Move ±4.8%
$27 $28 $29 $31 $32
NASDAQ · Healthcare · Biotechnology · $2.1B · Alpha Radar Buy · Power 65
Smart Money Score
Bullish 75
Insider+$13.1M
Congress1 trades
ETF Holdings
Key Statistics
Market Cap$2.1B
52W Range22.24-46
Volume1,283,322
Avg Volume868,313
Beta0.88
Dividend
Analyst Ratings
22 Buy 7 Hold 0 Sell
Consensus Buy
Company Info
CEOBrian Goff
Employees486
SectorHealthcare
IndustryBiotechnology
IPO Date2013-07-24
Websiteagios.com
88 Sidney Street
Cambridge, MA 02139-4169
US
617 649 8600
About Agios Pharmaceuticals, Inc.

Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers PYRUKYND (mitapivat) an activator of both wild-type and a variety of mutant pyruvate kinase, PK, enzymes for the treatment of hemolytic anemias; and AG-946 that is in Phase I clinical study for treating hemolytic anemias and other indications. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Recent Insider Trades

NameTypeSharesPriceDate
Viswanadhan Krishnan M-Exempt 8,100 2026-03-05
Viswanadhan Krishnan S-Sale 2,959 $27.80 2026-03-05
Viswanadhan Krishnan M-Exempt 8,100 2026-03-05
Washburn Theodore Ja S-Sale 5,272 $28.88 2026-03-03
Goff Brian M-Exempt 8,500 2026-03-02

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms